IMU Shares Imugene Limited
ASX · ASXLast in our picks 2026-10-26 — not in the current list; analysis below is from that screen
Immuno-oncology pipeline offers multiple shots on goal, though clinical execution remains the key valuation driver.
Signal breakdown
- ▸Pipeline catalysts could attract renewed speculative momentum.
- ▾Below 50-day MA (-33.1%)
- ▾Near 52-week low (0.8% of range)
Is IMU a buy right now?
Trend: IMU is trading below the 50-day average (-30.00%), RSI 40 — neutral momentum, with a 3-month return of -57.83%.
Valuation & quality: Imugene Limited trades on forward P/E -0.9, PEG 4.07, price-to-book 1.59; fundamentals show net margin 0.0%, return on equity -314.0%, revenue growth -59.8% year on year.
Analyst consensus: 3 analysts have a mean 12-month price target of A$0.23 (+557.1% vs the last close; range A$0.16 – A$0.28), consensus rating “none”.
Our screen: WATCH (score 0) — Immuno-oncology pipeline offers multiple shots on goal, though clinical execution remains the key valuation driver.
Computed from end-of-day data; not personal advice.
12-month price chart
Monthly returns
| Mar 26 | Apr 26 | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|---|---|
| -41.70% | -14.30% | +0.00% | +0.00% | -25.00% | -22.20% | -42.90% | +0.00% |
Fundamentals
Analyst price target
Technical signals
About Imugene Limited
Imugene Limited, a clinical-stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumours in Australia.
Sector: Healthcare · Industry: Biotechnology · Australia · 14 employees · Website
Related Biotech picks
Browse: all ASX stocks · Biotech picks · today's movers
Market data from end-of-day feeds; AI-generated research for educational purposes only — not investment advice.